Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00903175 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma

A Phase 2 study of Renal Cell Carcinoma, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
471
Enrollment target
20
Study locations

NCT00903175 is a Phase 2 study of Renal Cell Carcinoma that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 471 participants, above the 239-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00903175, a Phase 2 study of Renal Cell Carcinoma, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
471 participants
Enrollment target
20
Study locations

Study Summary

This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.

Conditions Studied

Renal Cell Carcinoma

Interventions

  • DRUG everolimus
  • DRUG sunitinib

Study Locations (20)

Florida

  • Lynn Cancer Institute - Boca Raton
  • University of Miami SC - Miami
  • MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando - Orlando

Georgia

  • University Cancer & Blood Center, LLC Dept of NE GCC (2) - Athens
  • Georgia Health Sciences University Dept. of MCG - Augusta
  • Summit Cancer Care - Savannah

Alabama

  • University of Alabama at Birmingham/ Kirklin Clinic Comprehensive CancerCenter (1) - Birmingham
  • University of South Alabama / Mitchell Cancer Institute Dept. of Mitchell Cancer Inst. - Mobile

California

  • University of California San Diego - Moores Cancer Center Dept of Moores Cancer Ctr (5) - La Jolla
  • University of California at Los Angeles Dept. of UCLA (3) - Los Angeles

Illinois

  • NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Dept.ofNorthwesternMemHospital - Chicago
  • Loyola University Medical Center /Cardinal Bernardin Cancer Cardinal Bernardin Cancer (3) - Maywood

Maryland

  • VA Maryland Health Care Dept.of GreenbaumCancerCent(7) - Baltimore
  • Weinberg Cancer Institute at Franklin Square Hospital - Baltimore

Arkansas

  • Highlands Oncology Group HighlandsOncGrp-Bentonville(2) - Fayetteville

Colorado

  • University of Colorado Dept. of Anschutz Cancer (2) - Aurora

Trial Details

FieldValue
Enrollment Target 471 participants
Start Date 2009-10
Est. Completion 2015-05
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00903175

The ClinicalTrials.gov registry entry for NCT00903175 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 471 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 239-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (97% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which everolimus is the first listed.

NCT00903175 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Alabama.

Frequently Asked Questions

What is clinical trial NCT00903175 about?

NCT00903175 is a clinical study titled "Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma". This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.

What is the current status of trial NCT00903175?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 471 participants. The study started on 2009-10. Estimated completion is 2015-05.

What conditions does trial NCT00903175 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma.

What interventions are being tested in trial NCT00903175?

The interventions under investigation include: everolimus (DRUG), sunitinib (DRUG).

Who is sponsoring clinical trial NCT00903175?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00903175 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.